The Potential Role of N6-Methyladenosine (m6A) Demethylase Fat Mass and Obesity-Associated Gene (FTO) in Human Cancers

References

• Dina C, Meyre D, Gallina S, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet. 2007;39:724–726. doi:10.1038/ng204817496892
   PubMed Web of Science ®Google Scholar
• Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316:889–894. doi:10.1126/science.114163417434869
   PubMed Web of Science ®Google Scholar
• Tschritter O, Preissl H, Yokoyama Y, Machicao F, Häring HU, Fritsche A. Variation in the FTO gene locus is associated with cerebrocortical insulin resistance in humans. Diabetologia. 2007;50:2602–2603. doi:10.1007/s00125-007-0839-117917711
   PubMed Web of Science ®Google Scholar
• Brennan P, McKay J, Moore L, et al. Obesity and cancer: mendelian randomization approach utilizing the FTO genotype. Int J Epidemiol. 2009;38(4):971–975. doi:10.1093/ije/dyp16219542184
   PubMed Web of Science ®Google Scholar
• Kaklamani V, Yi N, Sadim M, et al. The role of the fat mass and obesity associated gene (FTO) in breast cancer risk. BMC Med Genet. 2011;12:52. doi:10.1186/1471-2350-12-5221489227
   PubMed Web of Science ®Google Scholar
• da Cunha PA, de Carlos Back LK, Sereia AF, et al. Interaction between obesity-related genes, FTO and MC4R, associated to an increase of breast cancer risk. Mol Biol Rep. 2013;40:6657–6664. doi:10.1007/s11033-013-2780-324091943
   PubMed Web of Science ®Google Scholar
• Yamaji T, Iwasaki M, Sawada N, Shimazu T. Fat mass and obesity-associated gene polymorphisms, pre-diagnostic plasma adipokine levels and the risk of colorectal cancer: the Japan Public Health Center-based Prospective Study. 2020;15:e0229005.
   Google Scholar
• Xu D, Shao W, Jiang Y, Wang X, Liu Y, Liu X. FTO expression is associated with the occurrence of gastric cancer and prognosis. Oncol Rep. 2017;38:2285–2292. doi:10.3892/or.2017.590428849183
   PubMed Web of Science ®Google Scholar
• Lin Y, Ueda J, Yagyu K, et al. Association between variations in the fat mass and obesity-associated gene and pancreatic cancer risk: a case-control study in Japan. BMC Cancer. 2013;13:337. doi:10.1186/1471-2407-13-33723835106
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Murad A, Chen L, et al. Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. PLoS One. 2010;5:e13485. doi:10.1371/journal.pone.001348520976066
   PubMed Web of Science ®Google Scholar
• Li J, Zhu L, Shi Y, Liu J, Lin L, Chen X. m6A demethylase FTO promotes hepatocellular carcinoma tumorigenesis via mediating PKM2 demethylation. Am J Transl Res. 2019;11:6084–6092.31632576
   PubMed Web of Science ®Google Scholar
• Zhe H, Li J, Han Y, et al. The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA. Mol Carcinog. 2019;512:479–485.
   Google Scholar
• Boccaletto P, Machnicka MA, Purta E, et al. MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Res. 2018;46:D303–d7. doi:10.1093/nar/gkx103029106616
   PubMed Web of Science ®Google Scholar
• Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A. 1974;71:3971–3975. doi:10.1073/pnas.71.10.39714372599
   PubMed Web of Science ®Google Scholar
• Yue Y, Liu J, He C. RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation. Genes Dev. 2015;29:1343–1355. doi:10.1101/gad.262766.11526159994
   PubMed Web of Science ®Google Scholar
• Dominissini D, Moshitch-Moshkovitz S, Schwartz S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485:201–206. doi:10.1038/nature1111222575960
   PubMed Web of Science ®Google Scholar
• Maity A, Das B. N6-methyladenosine modification in mRNA: machinery, function and implications for health and diseases. 2016;283:1607–1630.
   Google Scholar
• Sun T, Wu R, Ming L. The role of m6A RNA methylation in cancer. Biomed Pharmacother. 2019;112:108613. doi:10.1016/j.biopha.2019.10861330784918
   PubMed Web of Science ®Google Scholar
• Huang Y, Su R, Sheng Y, et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell. 2019;35:677–91.e10. doi:10.1016/j.ccell.2019.03.00630991027
   PubMed Web of Science ®Google Scholar
• Shen XP, Ling X, Lu H, Zhou CX, Zhang JK, Yu Q. Low expression of microRNA-1266 promotes colorectal cancer progression via targeting FTO. Eur Rev Med Pharmacol Sci. 2018;22:8220–8226.30556861
   PubMed Web of Science ®Google Scholar
• Zhou S, Bai ZL, Xia D, Zhao ZJ, Zhao R, Wang YY. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting β-catenin through mRNA demethylation. 2018;57:590–597.
   Google Scholar
• Tang X, Liu S, Chen D, Zhao Z, Zhou J. The role of the fat mass and obesity-associated protein in the proliferation of pancreatic cancer cells. Oncol Lett. 2019;17:2473–2478.30719115
   PubMed Web of Science ®Google Scholar
• Doaei S, Gholamalizadeh M, Akbari ME, et al. Dietary carbohydrate promotes cell survival in cancer via the up-regulation of fat mass and obesity-associated gene expression level. BJU Int. 2019;26:8–17.
   Google Scholar
• Liu S, Huang M, Chen Z, et al. FTO promotes cell proliferation and migration in esophageal squamous cell carcinoma through up-regulation of MMP13. Exp Cell Res. 2020;389:111894.32035950
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhou D, Lai Y, et al. Estrogen induces endometrial cancer cell proliferation and invasion by regulating the fat mass and obesity-associated gene via PI3K/AKT and MAPK signaling pathways. Cancer Lett. 2012;319:89–97. doi:10.1016/j.canlet.2011.12.03322222214
   PubMed Web of Science ®Google Scholar
• Su R, Dong L, Li Y, et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer Cell. 2020;38(1):79–96.e11. doi:10.1016/j.ccell.2020.04.01732531268
   PubMed Web of Science ®Google Scholar
• Huang H, Wang Y, Kandpal M. FTO-dependent N6-methyladenosine modifications inhibit ovarian cancer stem cell self-renewal by blocking cAMP signaling. 2020.
   Google Scholar
• Gaudet MM, Yang HP, Bosquet JG, et al. No association between FTO or HHEX and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2010;19(8):2106–2109. doi:10.1158/1055-9965.EPI-10-051520647405
   PubMed Web of Science ®Google Scholar
• Hernández-Caballero ME, Sierra-Ramírez JA. Single nucleotide polymorphisms of the FTO gene and cancer risk: an overview. Mol Biol Rep. 2015;42(3):699–704. doi:10.1007/s11033-014-3817-y25387436
   PubMed Web of Science ®Google Scholar
• Salgado-Montilla JL, Rodríguez-Cabán JL, Sánchez-García J, Sánchez-Ortiz R, Irizarry-Ramírez M. Impact of FTO SNPs rs9930506 and rs9939609 in prostate cancer severity in a cohort of puerto rican men. Arch Cancer Res. 2017;5.
   Google Scholar
• Gholamalizadeh M, Jarrahi AM, Akbari ME, et al. Association between FTO gene polymorphisms and breast cancer: the role of estrogen. Expert Rev Endocrinol Metab. 2020;15:115–121. doi:10.1080/17446651.2020.173017632089015
   PubMed Web of Science ®Google Scholar
• Zeng X, Ban Z, Cao J, et al. Association of FTO mutations with risk and survival of breast cancer in a Chinese population. Dis Markers. 2015;2015:101032. doi:10.1155/2015/10103226146447
   PubMed Web of Science ®Google Scholar
• Kang Y, Liu F, Liu Y. Is FTOgene variant related to cancer risk independently of adiposity? An updated meta-analysis of 129,467 cases and 290,633 controls. Oncotarget. 2017;8(31):50987–50996. doi:10.18632/oncotarget.1644628881622
   PubMedGoogle Scholar
• Chen J, Davuluri RV, Matei D, et al. Specific TaqMan allelic discrimination assay for rs1477196 and rs9939609 single nucleotide polymorphisms of FTO gene demonstrated that there is no association between these SNPs and risk of breast cancer in Iranian women. Cancer Res. 2015;4:136.
   Google Scholar
• Tsugane S, Jafari Nedooshan J, Kargar S, et al. Lack of association of the fat mass and obesity associated (FTO) Gene rs9939609 polymorphism with breast cancer risk: a systematic review and meta-analysis based on case-control studies. PLoS One. 2017;18:1031–1037.
   Google Scholar
• Kusinska R, Górniak P, Pastorczak A, et al. Influence of genomic variation in FTO at 16q12.2, MC4R at 18q22 and NRXN3 at 14q31 genes on breast cancer risk. Mol Biol Rep. 2012;39(3):2915–2919. doi:10.1007/s11033-011-1053-221688152
   PubMed Web of Science ®Google Scholar
• Zhu RM, Lin W, Zhang W, et al. Modification effects of genetic polymorphisms in FTO, IL-6, and HSPD1 on the associations of diabetes with breast cancer risk and survival. J Cancer Res Clin Oncol. 2017;12:e0178850.
   Google Scholar
• Yang B, Thrift AP, Figueiredo JC, et al. Common variants in the obesity-associated genes FTO and MC4R are not associated with risk of colorectal cancer. Cancer Epidemiol. 2016;44:1–4. doi:10.1016/j.canep.2016.07.00327449576
   PubMed Web of Science ®Google Scholar
• Huang X, Zhao J, Yang M, Li M, Zheng J. Association between FTO gene polymorphism (rs9939609 T/A) and cancer risk: a meta-analysis. Eur J Cancer Care (Engl). 2017;26.
   Web of Science ®Google Scholar
• Li G, Chen Q, Wang L, Ke D, Yuan Z. Association between FTO gene polymorphism and cancer risk: evidence from 16,277 cases and 31,153 controls. Tumour Biol. 2012;33(4):1237–1243. doi:10.1007/s13277-012-0372-922396042
   PubMedGoogle Scholar
• Lurie G, Gaudet MM, Spurdle AB, et al. The obesity-associated polymorphisms FTO rs9939609 and MC4R rs17782313 and endometrial cancer risk in non-Hispanic white women. PLoS One. 2011;6(2):e16756. doi:10.1371/journal.pone.001675621347432
   PubMed Web of Science ®Google Scholar
• Sigurdson AJ, Brenner AV, Roach JA, et al. Selected single-nucleotide polymorphisms in FOXE1, SERPINA5, FTO, EVPL, TICAM1 and SCARB1 are associated with papillary and follicular thyroid cancer risk: replication study in a German population. Carcinogenesis. 2016;37(7):677–684. doi:10.1093/carcin/bgw04727207655
   PubMed Web of Science ®Google Scholar
• Deng X, Su R, Stanford S, Chen J. Critical enzymatic functions of FTO in obesity and cancer. Front Endocrinol (Lausanne). 2018;9:396. doi:10.3389/fendo.2018.0039630105001
   PubMed Web of Science ®Google Scholar
• Tan A, Dang Y, Chen G, Mo Z. Overexpression of the fat mass and obesity associated gene (FTO) in breast cancer and its clinical implications. Int J Clin Exp Pathol. 2015;8:13405–13410.26722548
   PubMed Web of Science ®Google Scholar
• Singh B, Kinne HE, Milligan RD, Washburn LJ, Olsen M, Lucci A. Important role of FTO in the survival of rare panresistant triple-negative inflammatory breast cancer cells facing a severe metabolic challenge. PLoS One. 2016;11(7):e0159072. doi:10.1371/journal.pone.015907227390851
   PubMed Web of Science ®Google Scholar
• Akbari ME, Gholamalizadeh M, Doaei S, Mirsafa F. FTO gene affects obesity and breast cancer through similar mechanisms: a new insight into the molecular therapeutic targets. Nutr Cancer. 2018;70(1):30–36. doi:10.1080/01635581.2018.139770929220587
   PubMed Web of Science ®Google Scholar
• Niu Y, Lin Z, Wan A, et al. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. 2019;18:46.
   Google Scholar
• Liu Y, Wang R, Zhang L, Li J, Lou K, Shi B. The lipid metabolism gene FTO influences breast cancer cell energy metabolism via the PI3K/AKT signaling pathway. Oncol Lett. 2017;13:4685–4690.28599470
   PubMed Web of Science ®Google Scholar
• Bojagora A, Saridakis V. USP7 manipulation by viral proteins. Virus Res. 2020;286:198076. doi:10.1016/j.virusres.2020.19807632603670
   PubMed Web of Science ®Google Scholar
• Li P, Liu HM. Recent advances in the development of ubiquitin-specific-processing protease 7 (USP7) inhibitors. Eur J Med Chem. 2020;191:112107. doi:10.1016/j.ejmech.2020.11210732092586
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang J, Chen C, Yuan H, Wen X, Sun H. USP7: target validation and drug discovery for cancer therapy. Med Chem. 2018;14:3–18.29065837
   PubMed Web of Science ®Google Scholar
• Liu J, Ren D, Du Z, Wang H, Zhang H, Jin Y. m 6 A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression. Biochem Biophys Res Commun. 2018;502(4):456–464. doi:10.1016/j.bbrc.2018.05.17529842885
   PubMed Web of Science ®Google Scholar
• Tsai LH, Wu JY, Cheng YW, et al. The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss. Oncogene. 2015;34:1641–1649.24793789
   PubMed Web of Science ®Google Scholar
• Qu Y, Dou P, Hu M, Xu J, Xia W, Sun H. circRNA‑CER mediates malignant progression of breast cancer through targeting the miR‑136/MMP13 axis. Mol Med Rep. 2019;19:3314–3320.30816475
   PubMed Web of Science ®Google Scholar
• Zhang H, Yang Q, Lian X, Jiang P, Cui J. Hypoxia-inducible Factor-1α (HIF-1α) promotes hypoxia-induced invasion and metastasis in ovarian cancer by targeting matrix metallopeptidase 13 (MMP13). Med Sci Monit. 2019;25:7202–7208. doi:10.12659/MSM.91688631587013
   PubMed Web of Science ®Google Scholar
• Zhang R, Zhu Z, Shen W, Li X, Dhoomun DK, Tian Y. Golgi Membrane Protein 1 (GOLM1) promotes growth and metastasis of breast cancer cells via regulating matrix metalloproteinase-13 (MMP13). Med Sci Monit. 2019;25:847–855. doi:10.12659/MSM.91166730695018
   PubMed Web of Science ®Google Scholar
• Li Y, Zheng D, Wang F, Xu Y, Yu H, Zhang H. Expression of demethylase genes, FTO and ALKBH1, is associated with prognosis of gastric cancer. Mol Cancer. 2019;64:1503–1513.
   Google Scholar
• Zahra K, Dey T, Ashish MSP, Pandey U. Pyruvate Kinase M2 and cancer: the role of PKM2 in promoting tumorigenesis. Front Oncol. 2020;10:159. doi:10.3389/fonc.2020.0015932195169
   PubMed Web of Science ®Google Scholar
• Zhang Z, Deng X, Liu Y, Liu Y. PKM2, function and expression and regulation. 2019;9:52.
   Google Scholar
• Zhao Y, You S, Yu YQ, et al. Decreased nuclear expression of FTO in human primary hepatocellular carcinoma is associated with poor prognosis. Int J Clin Exp Pathol. 2019;12:3376–3383.31934180
   PubMed Web of Science ®Google Scholar
• Wen L, Pan X, Yu Y, Yang B. Down-regulation of FTO promotes proliferation and migration, and protects bladder cancer cells from cisplatin-induced cytotoxicity. BMC Urol. 2020;20:39. doi:10.1186/s12894-020-00612-732299393
   PubMed Web of Science ®Google Scholar
• Zhuang C, Zhuang C, Luo X, et al. N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1α signalling axis. J Cell Mol Med. 2019;23:2163–2173. doi:10.1111/jcmm.1412830648791
   PubMed Web of Science ®Google Scholar
• Panajatovic M, Singh F, Duthaler U, Krähenbühl S, Bouitbir J. Role of PGC-1-alpha-associated mitochondrial biogenesis in statin-induced myotoxicity. Eur Cardiol. 2020;15:e35. doi:10.15420/ecr.2020.15.1.PO1232612695
   PubMedGoogle Scholar
• Safdar A, Little JP, Stokl AJ, Hettinga BP, Akhtar M, Tarnopolsky MA. Exercise increases mitochondrial PGC-1 α content and promotes nuclear-mitochondrial cross-talk to coordinate mitochondrial biogenesis. J Biol Chem. 2018;293:4953. doi:10.1074/jbc.EC118.00268229602880
   PubMed Web of Science ®Google Scholar
• Jones AW, Yao Z, Vicencio JM, Karkucinska-Wieckowska A, Szabadkai G. PGC-1 family coactivators and cell fate: roles in cancer, neurodegeneration, cardiovascular disease and retrograde mitochondria-nucleus signalling. Mitochondrion. 2012;12:86–99. doi:10.1016/j.mito.2011.09.00921983689
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu X, Liu J, Guo H, Xu H, Zhang G. PGC-1 alpha interacts with microRNA-217 to functionally regulate breast cancer cell proliferation. Biomed Pharmacother. 2017;85:541–548. doi:10.1016/j.biopha.2016.11.06227916422
   PubMed Web of Science ®Google Scholar
• Zou D, Dong L, Li C, Yin Z, Rao S, Zhou Q. The m(6)A eraser FTO facilitates proliferation and migration of human cervical cancer cells. Cancer Cell Int. 2019;19:321. doi:10.1186/s12935-019-1045-131827395
   PubMed Web of Science ®Google Scholar
• Tian W, Teng F, Gao J, et al. Estrogen and insulin synergistically promote endometrial cancer progression via crosstalk between their receptor signaling pathways. Horm Cancer. 2019;16:55–70.
   Google Scholar
• Yang B, Chen R, Liang X, et al. Estrogen enhances endometrial cancer cells proliferation by upregulation of prohibitin. J Cancer. 2019;10:1616–1621. doi:10.7150/jca.2821831205517
   PubMed Web of Science ®Google Scholar
• Rodriguez AC, Blanchard Z, Maurer KA, Gertz J. Estrogen signaling in endometrial cancer: a key oncogenic pathway with several open questions. 2019;10:51–63.
   Google Scholar
• Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B. The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019;698:120–128. doi:10.1016/j.gene.2019.02.07630849534
   PubMed Web of Science ®Google Scholar
• Roncolato F, Lindemann K, Willson ML, Martyn J, Mileshkin L. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. 2019;10:Cd012160.31588998
   PubMedGoogle Scholar
• Wanigasooriya K, Tyler R, Barros-Silva JD, Sinha Y, Ismail T, Beggs AD. Radiosensitising cancer using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or mammalian target of rapamycin (mTOR) Inhibitors. Cancers (Basel). 2020;12.
   PubMed Web of Science ®Google Scholar
• Braicu C, Buse M, Busuioc C, et al. A comprehensive review on MAPK: a promising therapeutic target in cancer. Int J Mol Sci. 2019;11.
   PubMedGoogle Scholar
• Dreas A, Mikulski M, Milik M, Fabritius CH, Brzózka K, Rzymski T. Mitogen-activated Protein Kinase (MAPK) interacting Kinases 1 and 2 (MNK1 and MNK2) as targets for cancer therapy: recent progress in the development of MNK inhibitors. Cancers (Basel). 2017;24:3025–3053.
   Google Scholar
• Lee S, Rauch J. Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. 2020;21.
   Google Scholar
• Stramucci L, Pranteda A, Bossi G. Insights of Crosstalk Between P53 Protein and the MKK3/MKK6/P38 MAPK Signaling Pathway in Cancer. 2018:10.
   Google Scholar
• Zhu Y, Shen J, Gao L, Feng Y. Estrogen promotes fat mass and obesity-associated protein nuclear localization and enhances endometrial cancer cell proliferation via the mTOR signaling pathway. Oncol Rep. 2016;35:2391–2397. doi:10.3892/or.2016.461326884084
   PubMed Web of Science ®Google Scholar
• Mirza-Aghazadeh-Attari M, Ekrami EM, Aghdas SAM, et al. Targeting PI3K/Akt/mTOR signaling pathway by polyphenols: implication for cancer therapy. Cell Biosci. 2020;255:117481.
   Google Scholar
• Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. 2020;10:31.
   Google Scholar
• Li Z, Weng H, Su R, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N(6)-Methyladenosine RNA Demethylase. Cancer Cell. 2017;31:127–141. doi:10.1016/j.ccell.2016.11.01728017614
   PubMed Web of Science ®Google Scholar
• Glasow A, Prodromou N, Xu K, von Lindern M, Zelent A. Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways. Blood. 2005;105:341–349. doi:10.1182/blood-2004-03-107415339853
   PubMed Web of Science ®Google Scholar
• Guibal FC, Moog-Lutz C, Smolewski P, et al. ASB-2 inhibits growth and promotes commitment in myeloid leukemia cells. J Biol Chem. 2002;277:218–224. doi:10.1074/jbc.M10847620011682484
   PubMed Web of Science ®Google Scholar
• Kohroki J, Fujita S, Itoh N, et al. ATRA-regulated Asb-2 gene induced in differentiation of HL-60 leukemia cells. FEBS Lett. 2001;505:223–228. doi:10.1016/S0014-5793(01)02829-011566180
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Imamura T, Yano M, et al. Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promoter region. Blood Cancer J. 2014;4:e205. doi:10.1038/bcj.2014.2524769646
   PubMed Web of Science ®Google Scholar
• Wang J, Muntean AG, Hess JL. ECSASB2 mediates MLL degradation during hematopoietic differentiation. Blood. 2012;119:1151–1161. doi:10.1182/blood-2011-06-36207922174154
   PubMed Web of Science ®Google Scholar
• Su R, Dong L, Li C, et al. R-2HG exhibits anti-tumor activity by targeting FTO/m(6)A/MYC/CEBPA signaling. Cell. 2018;172:90–105.e23. doi:10.1016/j.cell.2017.11.03129249359
   PubMed Web of Science ®Google Scholar
• D’Altri T, Wilhelmson AS, Schuster MB. et al. The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia. Haematologica;2020 haematol.2019.235150. doi:10.3324/haematol.2019.235150
   Web of Science ®Google Scholar
• Maxson JE, Schmidt L, Heyes E, Scheiblecker L, Eder T. CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex. Nat Commun. 2019;33:1608–1619.
   Google Scholar
• Braun TP, Okhovat M, Coblentz C, Carratt SA. Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia. 2019;10:5455.
   Google Scholar
• Van Der Werf I, Jamieson C. The Yin and Yang of RNA methylation: an imbalance of erasers enhances sensitivity to FTO demethylase small-molecule targeting in leukemia stem cells. Cancer Cell. 2019;35:540–541. doi:10.1016/j.ccell.2019.03.01130991023
   PubMed Web of Science ®Google Scholar
• Wen L, Yu Y, Lv H, He Y, Yang B. FTO mRNA expression in the lower quartile is associated with bad prognosis in clear cell renal cell carcinoma based on TCGA data mining. Ann Diagn Pathol. 2019;38:1–5. doi:10.1016/j.anndiagpath.2018.10.00930380400
   PubMed Web of Science ®Google Scholar
• Strick A, von Hagen F, Gundert L, et al. The N(6)-methyladenosine (m(6) A) erasers alkylation repair homologue 5 (ALKBH5) and fat mass and obesity-associated protein (FTO) are prognostic biomarkers in patients with clear cell renal carcinoma. 2020;125:617–24
   Google Scholar